dapirolizumab pegol: Clinical Trials

4 trials of dapirolizumab pegol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 not yet recruiting. 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Completed 3, Not yet recruiting 1

Follow dapirolizumab pegol: new trials by email Literature Review of dapirolizumab pegol trials Research Report on dapirolizumab pegol

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Placental Transfer of Dapirolizumab Pegol to the Infant(s) From Pregnant Study Participants With Active Systemic Lupus Erythematosus Who Are Administered Dapirolizumab Pegol
Dapirolizumab pegol (DZP) - Systemic Lupus Erythematosus
Phase 1Not yet recruitingUCB Biopharma SRL252026-11-152026-11-18
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants
BIIB133 (Dapirolizumab pegol), Placebo - Healthy Volunteers
Phase 1CompletedBiogen332020-10-142023-04-18
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
CDP7657, Placebo - Immune System Diseases, Autoimmune Diseases
Phase 1CompletedUCB Pharma242013-01-012015-07-16
Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
CDP7657, Placebo - Immune System Diseases, Autoimmune Diseases
Phase 1CompletedUCB Pharma442010-03-012013-01-04

Conditions studied

Lupus Erythematosus, Systemic (3)  ·  Autoimmune Diseases (2)  ·  Connective Tissue Diseases (2)  ·  Immune System Diseases (2)  ·  Skin and Connective Tissue Diseases (2)

Sponsors

UCB Pharma (2)  ·  Biogen (1)  ·  UCB Biopharma SRL (1)

Countries

Belgium (2)  ·  Bulgaria (2)  ·  Germany (2)  ·  Poland (1)  ·  Romania (1)  ·  Russia (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Amina Haggag, M.D (1)

Results publications

PMID 25784719, PMID 28780512

NIH funding

2009 (1), 2025 (1)